Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 7Pain, Postoperative 2Agnosia 2Sigmoidal Tumour 1Pancreatic Neoplasms 1Neoplasms 1Musculoskeletal Pain 1Hypotension 1Head and Neck Neoplasms 1Erector Spinae Block Analgesia 1Colorectal Neoplasms 1Brain Neoplasms 1Bradycardia 1Bites and Stings 1Abdominal Cancer Surgery 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × Levobupivacaine × Clear all
NCT02356640 2019-01-30

EUS-guided CGN for Inoperable Cancer

Chinese University of Hong Kong

Phase 2/3 Terminated
3 enrolled
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡